Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Panelist discusses how HER2-directed tumor-agnostic therapies represent an emerging treatment paradigm focused on targeting HER2 mutations regardless of cancer type. Current agents such as trastuzumab deruxtecan show promise across multiple tumor types that express HER2, moving beyond traditional cancer-specific approaches. This precision medicine strategy may expand treatment options and improve outcomes for patients with HER2-altered cancers who previously had limited therapeutic choices.
EP: 1.Introduction to HER2-Directed Tumor-Agnostic Approaches
EP: 2.HER2 Key Differences and Current Approaches to Biomarker Testing
EP: 3.Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
EP: 4.Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
EP: 5.Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
EP: 6.Future of HER2-Directed Tumor-Agnostic Therapies
Video content above is prompted by the following:
- Briefly review the current landscape of HER2-directed tumor-agnostic therapies. What are potential benefits of tumor-agnostic approaches in improving patient outcomes?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F555f5be80532573a6654f0b562c43e11aedf99df-1200x857.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“[O]ur findings show that large-scale lung cancer screening is both feasible and effective, and provide a framework for successful delivery of a population-based national program,” according to the study authors.")
